Tecentriq Hybreza Alternatives Compared
| Tecentriq Hybreza (atezolizumab / hyaluronidase) | Opdivo Qvantig (hyaluronidase / nivolumab) | Opdivo (nivolumab) |
|
|---|
| Tecentriq Hybreza (atezolizumab / hyaluronidase) | Opdivo Qvantig (hyaluronidase / nivolumab) | Opdivo (nivolumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Alveolar Soft Part Sarcoma, Hepatocellular Carcinoma, Melanoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer. Tecentriq Hybreza may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Colorectal Cancer, Head and Neck Cancer, Esophageal Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial... View more |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, and lung cancer. Fatigue, skin conditions, a cough, upper... View more |
Related suggestions Melanoma
|
|||||||||||||||||||||||
| More about Tecentriq Hybreza (atezolizumab / hyaluronidase) | More about Opdivo Qvantig (hyaluronidase / nivolumab) | More about Opdivo (nivolumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Opdivo has an average rating of 5.8 out of 10 from a total of 94 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 40% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Tecentriq Hybreza side effects |
View all Opdivo Qvantig side effects |
View all Opdivo side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Tecentriq Hybreza prices |
View all Opdivo Qvantig prices |
View all Opdivo prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
648 hours |
640.8 hours |
640.8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 695 drugs are known to interact with Tecentriq Hybreza:
|
A total of 661 drugs are known to interact with Opdivo Qvantig:
|
A total of 588 drugs are known to interact with Opdivo:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
December 27, 2024 |
December 22, 2014 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.